Differentiation problems: Clinical studies with dietary supplements;Klinische Studien mit Nahrungsergänzungsmitteln

Pharmazie in Unserer Zeit

Volumn 40, Issue 4, 2011, Pages 332-337

  Steffen, Christian ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CITRININ; MEVINOLIN; CHOLESTEROL;

ARTICLE; DIET SUPPLEMENTATION; HEALTH CENTER; CLINICAL TRIAL (TOPIC); DRUG LEGISLATION; ETHICS; FUNCTIONAL FOOD; GERMANY; HUMAN; METABOLISM; STANDARD;

CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; FUNCTIONAL FOOD; GERMANY; HUMANS; LEGISLATION, DRUG;

EID: 79959740522     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.201100428     Document Type: Article

References (44)

1. Dietary Supplement Health and Education Act of 1994. U.S. Food and Drug Administration Web site; http://www.fda.gov/RegulatoryInformation/Legislation/.
2. Harkey, M.R., et al., Variability in commercial ginseng products: an analysis of 25 preparations. Am. J. Clin. Nutr. (2001) 73, 1101-1106. (Pubitemid 32496951)
3. https://www.consumerlab.com/reviews/Red-Yeast-Rice-Supplements- Lovastatin-Monacolin/Red-Yeast-Rice/#results.
4. http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/ GuidanceDocuments/SmallBusinessesSmallEntityComplianceGuides/ucm238182.htm
5. http://www.fda.gov/Food/DietarySupplements/Alerts/
6. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108379. htm
7. Bent, S., et al., The Relative Safety of Ephedra Compared with Other Herbal Products. Ann. Intern. Med. (2003) 138, 468-471.
8. http://www.cbsnews.com/stories/2003/02/17/eveningnews/main540848.shtml
9. Erwägungsgrund 3 der VO 1924/2006/EG.
10. Artikel 6 der VO 1924/2006/EG.
11. Verordnung (EG) Nr. 353/2008/EG vom 18. April 2008, Anhang, Allgemeine Grundsätze.
12. z.B. Note for Guidance on Good Clinical Practice der International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (CPMP/ICH/135/95) und der Richtlinie über die Anwendung der guten klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Humanarzneimitteln (2001/20/EG).
13. Richtlinie 1999/21/EG der Kommission vom 25. März 1999 über diätetische Lebensmittel für besondere medizinische Zwecke.
14. Verordnung über diätetische Lebensmittel (Diätverordnung), § 4a.
15. Convention for the protection of Human Rights and dignity of the human being with regard to the application of biology and medicine: Convention on Human Rights and Biomedicine, Oviedo, 4.4.1997, http://conventions.coe.int/ Treaty/en/Treaties/html/164.htm
16. Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research, Strasbourg, 25.1.2005.
17. Artikel 4, Ziffer 29 des Explanatory Reports zur Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine, l.c.
18. Artikel 5, Ziffer 112-114 des Explanatory Reports zur Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine, l.c.
19. Richtlinie 2001/83/EG vom 6. November 2001 zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel (ABl. L 311 vom 28.11.2001, S. 67), Artikel 1, Ziffer 2b.
20. Erwägungsgrund 6 der Richtlinie 2002/46/EG.
21. The rules governing medicinal products in the European Union, Volume 10-Guidance document applying to clinical trials, Question & Answers. Version 7.0 (September 2010), SANCO/C/8/SF/dn D(2010) 712251.
22. http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/ guidance-doc-cosm-medicinal-en.pdf
23. http://ec.europa.eu/enterprise/sectors/medical-devices/files/meddev/ 2-1-3-rev-3-12-2009-en.pdf
24. EuGH, Urteil vom 15. 1. 2009-C-140/ 07.
25. Gren, F.A.C.: System der Pharmakologie oder Lehre von den Arzneimitteln, Erster Theil, 2. Auflage, Halle, Verlag der Waisenhausbuchhandlung 1798, § 2 (Seite 2).
26. http://www.bfr.bund.de/cm/238/verwendung-von-vitaminen-in-von- mineralstoffen-und-vitaminen-in-lebensmitteln.pdf
27. Promislow, J.H., et al., Retinol intake and bone mineral density in the elderly: the Rancho Bernardo study. J. Bone Mineral Res. (2002) 17, 1349-1358. (Pubitemid 34803818)
28. Feskanich, D., et al., Vitamin A intake and hip fractures among postmenopausal women. JAMA (2002) 287, 47-54. (Pubitemid 34251675)
29. Michaelsson, K., et al., Serum retinol levels and the risk of hip fracture. N. Engl. J. Med. (2003) 348, 287-294. (Pubitemid 36119983)
30. Steegers-Theunissen, R.P., et al., Periconceptional Maternal Folic Acid Use of 400 mg per Day Is Related to Increased Methylation of the IGF2 Gene in the Very Young Child. PLoS ONE (2009) 4, e7845.
31. Ness, A.R., et al., Taking folate in pregnancy and risk of maternal breast cancer. Brit. Med. J. (2004) 7479, 1375-3766.
32. Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus, draft: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2010/02/WC500073570.pdf
33. Mang, B., et al., Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur. J. Clin. Invest. (2006) 36, 340-344.
34. Hahn, A., Mang, B.: http://www.pharmazeutische-zeitung.de/index.php?id= 1587
35. Khan, A., t al., Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care (2003) 32, 15-18.
36. Vanschoonbeek, K., et al., Cinnamon Supplementation Does Not Improve Glycemic Control in Postmenopausal Type 2 Diabetes Patients. J. Nutr. (2006) 136, 977-980.
37. Oberlandesgericht Hamm, Urteil vom 07.08.2007-4 U 194/06.
38. Prasad, G.V., et al.: Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient Transplantation 74 (2002), 1200-1211.
39. Anonym: Rhabdomyolysis linked to Chinese red yeast rice. Prescrire Int. 17 (2008), 64.
40. DFG Senate Commission on Food Safety, Toxicological evaluation of red mould rice, 2005; http://www.dfg.de/download/pdf/dfg-im-profil/reden- stellungnahmen/2006/sklm-red-rice-en-06.pdf
41. http://www.efsa.europa.eu/en/panels/nda.htm
42. Scientific Opinion on the substantiation of a health claim related to "toothkind" drinks and reduction of tooth demineralisation pursuant to Article 13(5) of Regulation (EC) No 1924/2006; http://www.efsa.europa.eu/en/ efsajournal/pub/1884.htm
43. Scientific Opinion on the substantiation of a health claim related to water and reduced risk of development of dehydration and of concomitant decrease of performance pursuant to Article 14 of Regulation (EC) No 1924/2006; http://www.efsa.europa.eu/en/efsajournal/pub/1982.htm
44. Erwägungsgrund 23 der VO 1924/2006/EG.